Cargando…

罕见肿瘤新药研发的思考

In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346156/
https://www.ncbi.nlm.nih.gov/pubmed/35899439
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.26
_version_ 1784761583869624320
collection PubMed
description In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of basic research and the discovery of new molecular tumor typing make "rare tumors" a dynamic concept. The scope of "rare tumors" may gradually expand with the precise development of treatment; or as the knowledge of tumors gradually develops from histocytology to the molecular level, It is possible that certain tumors with specific mutations can be combined into a group of non-rare "pan-tumors". Rare tumors are characterized by both rare diseases and tumors. Its drug research and development should not only meet the requirements of tumor drug research and development, but also adapt to the characteristics of rare diseases. Therefore, in the drug research and development, we can refer to the research and development principle of rare disease drugs, combine with the characteristics of tumor diseases, make full use of non-rare tumor clinical trials, make full use of scientific tools and exquisite trial design, and realize the promotion of the research and development of rare tumor drugs. This paper will summarize the thoughts in the review of new drugs in the field of rare tumors, in order to provide guidance for the industry.
format Online
Article
Text
id pubmed-9346156
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-93461562022-08-17 罕见肿瘤新药研发的思考 Zhongguo Fei Ai Za Zhi 肺癌创新药物研发 In recent years, China's anti-tumor drugs has shown a continuous growth trend, and the activity of anti-tumor research and development in China accounts for a higher proportion in the world. However, further analysis of research and development hotspots show that the research and development of anti-tumor drugs is uneven among different tumor types. Due to the small number of the patients, it is difficult to conduct clinical trials, resulting in less drug development in the field of rare tumors. However, patients' treatment needs will also bring potential opportunities for pharmaceutical companies. The development of basic research and the discovery of new molecular tumor typing make "rare tumors" a dynamic concept. The scope of "rare tumors" may gradually expand with the precise development of treatment; or as the knowledge of tumors gradually develops from histocytology to the molecular level, It is possible that certain tumors with specific mutations can be combined into a group of non-rare "pan-tumors". Rare tumors are characterized by both rare diseases and tumors. Its drug research and development should not only meet the requirements of tumor drug research and development, but also adapt to the characteristics of rare diseases. Therefore, in the drug research and development, we can refer to the research and development principle of rare disease drugs, combine with the characteristics of tumor diseases, make full use of non-rare tumor clinical trials, make full use of scientific tools and exquisite trial design, and realize the promotion of the research and development of rare tumor drugs. This paper will summarize the thoughts in the review of new drugs in the field of rare tumors, in order to provide guidance for the industry. 中国肺癌杂志编辑部 2022-07-20 /pmc/articles/PMC9346156/ /pubmed/35899439 http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.26 Text en 版权所有©《中国肺癌杂志》编辑部2022 https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle 肺癌创新药物研发
罕见肿瘤新药研发的思考
title 罕见肿瘤新药研发的思考
title_full 罕见肿瘤新药研发的思考
title_fullStr 罕见肿瘤新药研发的思考
title_full_unstemmed 罕见肿瘤新药研发的思考
title_short 罕见肿瘤新药研发的思考
title_sort 罕见肿瘤新药研发的思考
topic 肺癌创新药物研发
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9346156/
https://www.ncbi.nlm.nih.gov/pubmed/35899439
http://dx.doi.org/10.3779/j.issn.1009-3419.2022.101.26
work_keys_str_mv AT hǎnjiànzhǒngliúxīnyàoyánfādesīkǎo
AT hǎnjiànzhǒngliúxīnyàoyánfādesīkǎo
AT hǎnjiànzhǒngliúxīnyàoyánfādesīkǎo